# References

Brown, R. P., et al. “Physiological Parameter Values for Physiologically Based Pharmacokinetic Models.” Toxicology and Industrial Health, vol. 13, no. 4, July 1997, pp. 407–484. https://doi.org/10.1177/074823379701300401

Deepika, D., and V. Kumar. “The Role of ‘Physiologically Based Pharmacokinetic Model (PBPK)’ New Approach Methodology (NAM) in Pharmaceuticals and Environmental Chemical Risk Assessment.” International Journal of Environmental Research and Public Health, vol. 20, no. 4, 16 Feb. 2023, p. 3473. https://doi.org/10.3390/ijerph20043473

DrugBank. “Propranolol.” DrugBank, 13 June 2024, https://go.drugbank.com/drugs/DB00571

Evans, G. H., et al. “The Disposition of Propranolol. III. Decreased Half-Life and Volume of Distribution as a Result of Plasma Binding in Man, Monkey, Dog and Rat.” The Journal of Pharmacology and Experimental Therapeutics, vol. 186, no. 1, 31 Jan. 2025, pp. 114–122. https://doi.org/10.1016/S0022-3565(25)29572-6

Hung, D. Y., et al. “Disposition Kinetics of Propranolol Isomers in the Perfused Rat Liver.” The Journal of Pharmacology and Experimental Therapeutics, vol. 311, no. 2, 3 Jan. 2025, pp. 822–829. https://doi.org/10.1124/jpet.104.070011

Jamei, M., et al. “Population-Based Mechanistic Prediction of Oral Drug Absorption.” The AAPS Journal, vol. 11, no. 2, 2009, pp. 225–237. https://doi.org/10.1208/s12248-009-9099-y

Jones, H. M., and K. R. Yeo. “Basic Concepts in Physiologically Based Pharmacokinetic Modeling in Drug Discovery and Development.” CPT: Pharmacometrics & Systems Pharmacology, vol. 2, no. 8, 2013, pp. 1–12. https://doi.org/10.1038/psp.2013.41

Jones, H. M., et al. “A Novel Strategy for Physiologically Based Predictions of Human Pharmacokinetics.” Clinical Pharmacokinetics, vol. 45, no. 5, 2006, pp. 511–542. https://doi.org/10.2165/00003088-200645050-00006

Kaufman, D. P., et al. “Physiology, Glomerular Filtration Rate (GFR).” StatPearls, National Library of Medicine, 2023, https://www.ncbi.nlm.nih.gov/books/NBK500032/

Lee, H. B., and M. D. Blaufox. “Blood Volume in the Rat.” Journal of Nuclear Medicine, vol. 26, no. 1, Jan. 1985, pp. 72–76. https://pubmed.ncbi.nlm.nih.gov/3965655/

Lee, M., et al. “Prediction of Pharmacokinetics of IDP-73152 in Humans Using Physiologically-Based Pharmacokinetics.” Pharmaceutics, vol. 14, no. 6, 28 May 2022, p. 1157. https://doi.org/10.3390/pharmaceutics14061157

Mondal, H., and L. Saran. “Hematocrit (HCT).” StatPearls, National Library of Medicine, 6 Oct. 2024, https://www.ncbi.nlm.nih.gov/books/NBK542276/

Nicolaï, J., et al. “Verapamil Hepatic Clearance in Four Preclinical Rat Models: Towards Activity‐Based Scaling.” Biopharmaceutics & Drug Disposition, vol. 36, no. 7, 11 May 2015, pp. 462–480. https://doi.org/10.1002/bdd.1959

Potter, D., et al. “Character of Function and Size in Kidney during Normal Growth of Rats.” Pediatric Research, vol. 3, no. 1, 1 Jan. 1969, pp. 51–59. https://doi.org/10.1203/00006450-196901000-00007

Reigner, B., et al. “Comparative Pharmacokinetics of Propranolol after Administration into the Portal and Systemic Circulation in the Rat.” Journal of Pharmacology, vol. 38, no. 2, 1989, pp. 112–119. https://doi.org/10.1159/000136352

Rostami-Hodjegan, A. “Physiologically Based Pharmacokinetics Joined with In Vitro–In Vivo Extrapolation of ADME: A Marriage under the Arch of Systems Pharmacology.” Clinical Pharmacology & Therapeutics, vol. 92, no. 1, 2012, pp. 50–61. https://doi.org/10.1038/clpt.2012.65

Rowland, M., et al. “Physiologically Based Pharmacokinetics in Drug Development and Regulatory Science: A Workshop Report.” Clinical Pharmacokinetics, vol. 45, no. 5, 2006, pp. 507–526. https://doi.org/10.2165/00003088-200645050-00006

Rowland, M., and T. N. Tozer. Clinical Pharmacokinetics and Pharmacodynamics: Concepts and Applications. 4th ed., Wolters Kluwer Health/Lippincott Williams & Wilkins, 2011

Shahrokhi, M., and V. Gupta. “Propranolol.” StatPearls, National Library of Medicine, 1 May 2023, https://www.ncbi.nlm.nih.gov/books/NBK557801/

Shand, D. G., et al. “The Disposition of Propranolol.” Pharmacology, vol. 8, no. 4–6, 1 Jan. 1972, pp. 344–352. https://doi.org/10.1159/000136352

Silberx, B. M., et al. “Dose-Dependent Elimination of Propranolol and Its Major Metabolites in Humans.” Journal of Pharmaceutical Sciences, vol. 72, no. 7, 1 July 1983, pp. 725–732. https://doi.org/10.1002/jps.2600720703

Simcyp Simulator. Version 22, Certara UK Limited, 2023

Singh, K., et al. “Determination of in Vivo Hepatic Extraction Ratio from in Vitro Metabolism by Rat Hepatocytes.” Drug Metabolism and Disposition, vol. 19, no. 5, 1991, pp. 990–996. https://pubmed.ncbi.nlm.nih.gov/1686248/

Taegtmeyer, A. B., et al. “A Study of the Relationship between Serum Bile Acids and Propranolol Pharmacokinetics and Pharmacodynamics in Patients with Liver Cirrhosis and in Healthy Controls.” PLOS ONE, vol. 9, no. 6, 6 June 2014, pp. e97885–e97885. https://doi.org/10.1371/journal.pone.0097885

Taylor, E. A., and P. Turner. “The Distribution of Propranolol, Pindolol and Atenolol between Human Erythrocytes and Plasma.” British Journal of Clinical Pharmacology, vol. 12, no. 4, Oct. 1981, pp. 543–548. https://doi.org/10.1111/j.1365-2125.1981.tb01263.x

Zhao, P., et al. “Applications of Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulation during Regulatory Review.” Clinical Pharmacology & Therapeutics, vol. 92, no. 1, 2012, pp. 1–4. https://doi.org/10.1038/clpt.2012.113
